Dysregulated expression of SKP2 and its role in hematological malignancies

Abstract

S-phase kinase-associated protein 2 (SKP2) is a well-studied F-box protein and a critical part of the Skp1-Cul1-Fbox (SCF) E3 ligase complex. It controls cell cycle by regulating the expression level of p27 and p21 through ubiquitination and proteasomal degradation. SKP2-mediated loss of p27Kip1 is associated with poor clinical outcome in various types of cancers including hematological malignancies. It is however well established that SKP2 is an oncogene, and its targeting may be an attractive therapeutic strategy for the management of hematological malignancies. In this article, we have highlighted the recent findings from our group and other investigators regarding the role of SKP2 in the pathogenesis of hematological malignancies.

Keywords:

• Proteasome pathways
• SKP2
• proto-oncogene
• p27Kip1
• hematological malignancies

Acknowledgments

This study was supported by a research grant from Medical Research Center (Project # 15145/15), Hamad Medical Corporation, Doha, the State of Qatar.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1359740.

Additional information

Funding

Medical Research Center15145/15

Hamad Medical Corporation10.13039/100007833This study was supported by a research grant from Medical Research Center (Project # 15145/15), Hamad Medical Corporation, Doha, the State of Qatar.